Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints ex-Pfizer exec as global head of oncology

Maya Martinez-Davis succeeds Andrew Schiermeier in the role

Merck Maya Martinez-DavisDarmstadt, Germany-based Merck has appointed Maya Martinez-Davis as the new global head of its oncology franchise.

Reporting to Merck's Rehan Verjee, chief marketing and strategy officer of its healthcare business, Martinez-Davis will be based out of the firm's Massachusetts office.

In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell lung cancer therapy, which is expected in 2017.

Prior to joining Merck, Martinez-Davis had spent over a decade at Pfizer, occupying increasingly senior executive roles, most recently of which was as North America regional president, oncology.

Verjee said: “Maya's considerable experience in oncology, which includes the recent successful launch of Ibrance in the USA, make her a valued addition to our team as we endeavor to bring new therapeutic options to patients living with cancer.

“This is a very exciting time for our company as we advance our promising oncology and immuno-oncology pipeline and attract leading industry talent to Merck.”

29th April 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics